OncLive TV

Jennifer Chan, MD, MPH, discusses the FDA approval of cabozantinib for previously treated, advanced well-differentiated (extra) pancreatic neuroendocrine tumors.

Aydah Alawadhi, MBBS, discusses the effect of obesity and overweight status on patient outcomes across subgroups of early-stage breast cancer.

Bhagirathbhai Dholaria, MBBS, discusses future directions for research with P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma.

Benjamin L. Maughan, MD, PharmD, discusses the need for improved update of treatment intensification in metastatic hormone-sensitive prostate cancer.

Alicia Morgans, MD, MPH, discusses the importance of managing bone and cardiac health in patients with prostate cancer receiving systemic therapy.

Chandler Park, MD, discusses key factors that facilitate decisions between the available frontline treatment regimens for patients with bladder cancer.

Ramez N. Eskander, MD, discusses the key efficacy findings and future implications of the NIVEC trial of nivolumab in resectable dMMR endometrial cancer.

David Rimm, MD, PhD, discusses how FDA-approved IHC assays may lack reproducibility in real-world settings in breast cancer.

Alex Bowman, MD, discusses the need for early symptom recognition, genetic risk evaluation, and research support to improve RCC detection and outcomes.

Guru P. Sonpavde, MD, discusses the INTerpath-005 study evaluating adjuvant V940 plus pembrolizumab in resected high-risk MIBC.

Jenny Paredes, PhD, discusses how increased dietary fiber was associated with improved 24-month survival and reduced lower GI aGVHD in allo-HCT recipients.

Eunice S. Wang, MD, discusses the role of menin inhibitors like revumenib in AML with KMT2A rearrangements or NPM1 mutations.

Mark D. Tyson, II, MD, MPH, discusses challenges choosing between nadofaragene firadenovec, nogapendekin alfa, and pembrolizumab in BCG-unresponsive NMIBC.

Alicia Morgans, MD, MPH, discusses how a lack of PSA doubling time documentation may lead to undertreatment in high-risk BCR prostate cancer.

Julie Lang, MD, discusses real-world safety data from for the KEYNOTE-522 regimen in early triple-negative breast cancer.

Amrita Krishnan, MD, highlights key innovations in multiple myeloma, including GPRC5D-targeted agents and evolving strategies in T-cell–directed therapy.

Syed Abbas Ali, MBBS, discusses treatment decisions for patients with R/R myeloma for whom CAR T-cell therapy and bispecific antibodies are both options.

Oleg Gluz, MD, discusses findings from subgroup analyses of the WSG-TP-II trial of neoadjuvant de-escalated chemotherapy in HER2-positive breast cancer.

R. Lor Randall, MD, FACS, discusses the application of a bioengineered bone marrow matrix as a three-dimensional model to analyze osteosarcoma cell behavior under varying oxygen tensions.

Jeffrey Zonder, MD, discusses the need for increased awareness in multiple myeloma.

Shilpa Gupta, MD, discusses OS outcomes with first-line maintenance avelumab plus BSC in advanced urothelial carcinoma based on diabetes mellitus.

Hyun-Woong Cho, MD, PhD, discusses the efficacy of maintenance therapy with niraparib plus bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Zamtocabtagene autoleucel was associated with a manageable safety profile with no grade 3 or higher CRS and low ICANS rates in relapsed/refractory DLBCL.

Alan H. Bryce, MD, discusses treatment comparisons of ARPI efficacy according to disease volume and timing of metastasis development in mHSPC.

Timothy S. Fenske, MD, MS, discusses survival outcomes in patients with MCL who remained MRD positive following consolidative auto-HCT.

Sheela Rao, MBBS, MD, FRCP, highlights the current treatment landscape in the localized anal cancer setting for anal cancer Awareness Day, March 21.

Yufei Liu, MD, PhD, discusses SBRT and IMRT strategies and the role of radiation in patients with colorectal cancer.

Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.

R. Lor Randall, MD, FACS, discusses how to select between vimseltinib, pexidartinib, and surgery for patients with tenosynovial giant cell tumor.